Diagnostic Medical Systems S.A (ALDMS) Fair Value & Analysis
Healthcare · FR · Market cap €32.5M
Fair value as of: Jun 24, 2026
Analysis
Diagnostic Medical Systems S.A (ALDMS) currently trades at €1.27, while our model-based Fair Value estimate is €1.83 — implying the stock looks roughly 44.1% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and long leg exams. It also provides mobiles under the !M1, ONYX, Rafale/Rafale DR, and !Mobile Wall Stand names; c-arm products under the EVO R+ FP ADAM and EVO + / EVO R+ names; retrofit kits; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Diagnostic Medical Systems S.A (ALDMS) undervalued?
What is the fair value of ALDMS?
What is the quality score of ALDMS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.